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cardiovascular risk factor [1]. Although only 5–10%
of hypertensive patients have an identifiable cause
for it (that is, secondary hypertension), the vast
majority have essential (idiopathic or primary) hy-
pertension [2]. The causes are in general poorly
understood, even if essential hypertension is charac-
terized as a highly (around 3040%) hereditable
disease [3]. In line with this observation, epidemio-
logical studies could identify several genes and
genetic variants associated with increased blood
pressure (BP) [4]. However, a surprising result of
these studies was that these genetic variants con-
tribute only a minor part of the phenotypic vari-
ation in BP. This discrepancy, between the expected
and observed contribution of these genetic variants,
is termed ‘missed heritability’ [5]. Several theories
have been suggested to explain this phenomenon,
and one of the most intriguing hypotheses is that
epigenetic regulation of gene expressionmay impor-
tantly account for this variance [6]. The term ‘epi-
genetic’ refers to mechanisms that regulate gene
expression without affecting the DNA sequence
itself. Importantly, epigenetic activity is increased
and particularly vulnerable to environmental
insults during the embryonic, fetal and early post-
natal periods [7]. In line with this concept, vulner-
able periods during early life known to be associated
with fetal programming of cardiovascular disease
coincide with increased epigenetic activity. The
review article by Scherrer et al. [8] highlights the
potential contribution of fetal programming to the
pathogenesis of arterial hypertension: studies in
young offspring of mothers suffering from pre-
eclampsia [9] and in apparently healthy children
conceived by assisted reproductive technologies
(ART) [10,11] have shown that these children dis-
play premature vascular aging and increased BP.
Studies in animal models of these two entities have
shown that epigenetic dysregulation with conse-
quent altered expression of genes important for
BP regulation [that is, endothelial nitric oxide
synthase (eNOS)] plays a central role in theht © 2015 Wolters Kluwe
rs Kluwer Health, Inc. All rights resealarming observation is that epigenetic alterations
occurring during early life may persist throughout
the lifespan of the individual and sometimes can be
transmitted to the next generation. Consistently
with this concept, vascular dysfunction in the prog-
eny of male ART mice mated with normal females is
comparable to that observed in the fathers and is
associated with similar alterations of the methyl-
ation of genes in the vasculature [13].
The observation that lowbirthweight inhumans
is associated with epigenetic alterations [14] and
increased BP represents another example for this
hypothesis [15]. Bruno et al. [16] review the most
relevantpathophysiologicalmechanisms involved in
the association between birth weight and increased
risk for arterial hypertension in adulthood. An
important observation in this context is that adverse
events during early life are invariably associated with
premature vascular aging (that is, endothelial dys-
function, increased arterial stiffness and increased
carotid intima-media thickness) that is already
detectable during childhood and may develop into
arterial hypertension in adulthood [7,17]. This has
two important consequences: the detection of sub-
populations at risk at an early stage may allow the
prevention of future development of cardiovascular
diseases, and as a practical consequence, therefore,
‘early life’ history and BP measurement in children
should be part of the routine workup for the assess-
ment of cardiovascular risk in general practice. The
review of Santi et al. [18] points out this relevant
aspect, which has been recently discussed by the
US Preventive Services Task Force [19]. Althoughr Health, Inc. All rights reserved.
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Hypertensionthe Task Force concluded that ‘current evidence is
insufficient to assess the balance of benefits and
harms of screening for elevated blood pressure in
apparently healthy children and adolescents to pre-
vent subsequent cardiovascular disease in childhood
or adulthood’, Santi et al. (in accordance with other
guidelines)underline the importanceof screening for
high BP at regular intervals, as increased BP during
childhood tracks into adulthood [20] and almost half
of adults with arterial hypertension had high BP
values in childhood [21]. Finally, the review by Raio
et al. [22] emphasizes the contribution of arterial
hypertension in pregnancy to perinatal morbidity
and mortality of both the mother and her child
and discusses the relevance of adequate prevention
and treatment of these hypertensive disorders. An
important aspect to consider is the fact that offspring
of mothers suffering from pre-eclampsia are at
increased risk for stroke in adulthood [23]. Therefore,
prevention and/or treatment of hypertension in
pregnancy is expectednotonly todecreasemorbidity
and mortality in the mother, but also to prevent
vascular dysfunction and premature cardiovascular
morbidity and mortality in the offspring [9]. In sum-
mary, adverse events during early life are associated
with arterial hypertension and increased cardiovas-
cular morbidity and mortality in adulthood. Studies
in experimental animalmodels show that pathologic
insults during fetal life cause epigenetic alterations of
genes regulating important pathways of blood pres-
sure regulation that are heritable. These studies could
suggest that epigenetic alterationsmayalso underpin
the fetal programming of arterial hypertension (and
premature cardiovascular morbidity and mortality)
in humans and thereby explain, at least in part, the
‘missing heritability’ of essential hypertension. As a
practical consequence, ‘early life’ history should
become part of the routine in the assessment of
cardiovascular risk in children and adolescents, and
if suspect, it should be followed by ambulatory BP
measurement and assessment of vascular function.
This should allow early intervention and prevention
of future morbidity and mortality in persons at risk.
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